arginine vasopressin has been researched along with satavaptan in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (33.33) | 18.2507 |
| 2000's | 12 (57.14) | 29.6817 |
| 2010's | 2 (9.52) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishii, N; Kusayama, T; Saito, M; Sugimoto, T; Tahara, A; Tanaka, A; Tomura, Y; Tsukada, J; Uchida, W; Wada, K; Yatsu, T | 1 |
| Akerlund, M; Bossmar, T; Brouard, R; Kostrzewska, A; Laudanski, T; Lemancewicz, A; Serradeil-Le Gal, C; Steinwall, M | 1 |
| Aumelas, A; Balestre, MN; Barberis, C; Cotte, N; Durroux, T; Hibert, M; Mahé, E; Manning, M; Morin, D; Mouillac, B; Phalipou, S | 1 |
| Double-Cazanave, E; Garcia, C; Guillon, G; Maffrand, JP; Pascal, M; Raufaste, D; Serradeil-Le Gal, C | 1 |
| Bankir, L; Barberis, C; Brossard, G; Chicot, D; Foulon, L; Galindo, G; Garcia, C; Garcia, G; Guillon, G; Jard, S; Lacour, C; Le Fur, G; Maffrand, JP; Marty, E; Nisato, D; Pouzet, B; Raufaste, D; Serradeil-Le Gal, C; Valette, G; Vilain, P | 1 |
| Serradeil-Le Gal, C | 1 |
| Dayanithi, G; Gouzénes, L; Moos, FC; Richard, P; Sabatier, N | 1 |
| Dayanithi, G; Gouzènes, L; Moos, FC | 1 |
| Cros, G; Laurent, F; Méchaly, I; Portet, K; Serrano, J | 1 |
| Angers, S; Arthus, MF; Bernier, V; Bichet, DG; Bouvier, M; Laperrière, A; Lonergan, M; Morello, JP; Morin, D; Petäjä-Repo, U; Salahpour, A | 1 |
| Ishii, N; Kusayama, T; Tahara, A; Tanaka, A; Taniguchi, N; Tomura, Y; Tsukada, J; Uchida, W; Yatsu, T | 1 |
| Chevaleyre, V; Desarménien, MG; Moos, FC | 1 |
| Barberis, C; Brossard, G; Griebel, G; Guillon, G; Lacour, C; Le Fur, G; Maffrand, JP; Nisato, D; Pascal, M; Pruss, R; Scatton, B; Serradeil-Le Gal, C; Simiand, J; Soubrié, P; Wagnon, J | 1 |
| Ali, F; Ghali, JK; Guglin, M; Vaitkevicius, P | 1 |
| Shibasaki, M; Tahara, A; Tomura, Y; Tsukada, J; Yatsu, T | 1 |
| Bankir, L; Bardoux, P; Bichet, DG; Bouby, N; Perucca, J | 1 |
| Ginès, P; Guevara, M | 1 |
| Boerrigter, G; Burnett, JC; Costello-Boerrigter, LC | 1 |
| Bernard, A; Bonventre, JV; Chagnon, F; Guindi, C; Lesur, O; Plante, GE; Vaidya, VS | 1 |
| Boone, M; Deen, PM; Kortenoeven, M; Robben, JH | 1 |
| Iwao, H; Izumi, Y; Miura, K | 1 |
5 review(s) available for arginine vasopressin and satavaptan
| Article | Year |
|---|---|
Nonpeptide antagonists for vasopressin receptors. Pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist.
Topics: Adenylyl Cyclases; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Deamino Arginine Vasopressin; Dogs; Heart Failure; Humans; Kidney; Morpholines; Rats; Rats, Inbred BB; Receptors, Vasopressin; Spiro Compounds; Water-Electrolyte Imbalance | 1998 |
Therapeutic potential of vasopressin receptor antagonists.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan | 2007 |
Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Humans; Hyponatremia; Liver Cirrhosis; Morpholines; Sodium; Spiro Compounds | 2008 |
Pharmacology of vasopressin antagonists.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Benzodiazepines; Heart Failure; Humans; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan | 2009 |
Therapeutic potential of vasopressin-receptor antagonists in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Benzazepines; Body Water; Clinical Trials as Topic; Disease Models, Animal; Heart Failure; Homeostasis; Humans; Hyponatremia; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan; Ventricular Remodeling | 2014 |
16 other study(ies) available for arginine vasopressin and satavaptan
| Article | Year |
|---|---|
Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
Topics: Animals; Benzazepines; Binding, Competitive; Calcium; CHO Cells; Cricetinae; Cyclic AMP; Humans; Indoles; Morpholines; Piperidines; Pyrrolidines; Quinolones; Receptors, Vasopressin; Spiro Compounds; Transfection; Tritium | 1998 |
Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Cell Line; Cesarean Section; Female; Hormone Antagonists; Humans; Indoles; Morpholines; Myometrium; Obstetric Labor, Premature; Oxytocin; Pregnancy; Pyrrolidines; Receptors, Oxytocin; Spiro Compounds; Vasopressins | 1999 |
Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding.
Topics: Amino Acid Sequence; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Binding Sites; Cell Membrane; Conserved Sequence; COS Cells; Humans; Ligands; Molecular Sequence Data; Mutagenesis, Site-Directed; Receptors, Vasopressin | 2000 |
Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Binding, Competitive; Cattle; CHO Cells; Cricetinae; Dogs; Haplorhini; Homeostasis; Humans; Kidney; Kinetics; Morpholines; Rabbits; Radioligand Assay; Rats; Spiro Compounds; Swine; Tritium; Vasopressins; Water-Electrolyte Balance | 2000 |
Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
Topics: Adenylyl Cyclases; Administration, Oral; Adrenal Glands; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Autoradiography; Benzazepines; Binding, Competitive; Furosemide; Hydrochlorothiazide; Kidney; Molecular Structure; Morpholines; Potassium; Rats; Sodium; Spiro Compounds; Urine | 1996 |
V1a- and V2-type vasopressin receptors mediate vasopressin-induced Ca2+ responses in isolated rat supraoptic neurones.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Calcium; Deamino Arginine Vasopressin; In Vitro Techniques; Indoles; Kinetics; Male; Morpholines; Neurons; Pyrrolidines; Rats; Rats, Wistar; Receptors, Vasopressin; Spiro Compounds; Supraoptic Nucleus; Transcription, Genetic; Vasoconstrictor Agents; Vasopressins | 1999 |
Vasopressin(4-9) fragment activates V1a-type vasopressin receptor in rat supraoptic neurones.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Calcium; Fluorescent Dyes; Fura-2; Hormone Antagonists; In Vitro Techniques; Indoles; Male; Morpholines; Neurons; Peptide Fragments; Pyrrolidines; Rats; Rats, Wistar; Receptors, Vasopressin; Spiro Compounds; Supraoptic Nucleus | 1999 |
Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Aorta; Arginine Vasopressin; Deamino Arginine Vasopressin; Endothelium, Vascular; Hemostatics; Hormone Antagonists; Indoles; Male; Morpholines; Pyrrolidines; Rats; Rats, Wistar; Spiro Compounds | 1999 |
Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Cell Line; Cell Membrane; COS Cells; Diabetes Insipidus, Nephrogenic; Flow Cytometry; Humans; Intracellular Fluid; Molecular Chaperones; Morpholines; Mutagenesis; Protein Folding; Pyrroles; Receptors, Vasopressin; Spiro Compounds | 2000 |
Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Binding, Competitive; Calcium; Cell Membrane; CHO Cells; Cricetinae; Cyclic AMP; Dose-Response Relationship, Drug; Female; Humans; Indoles; Morpholines; Muscle, Smooth; Oxytocin; Piperidines; Pyrrolidines; Radioligand Assay; Receptors, Oxytocin; Receptors, Vasopressin; Spiro Compounds; Tritium; Uterus | 2001 |
Interplay between presynaptic and postsynaptic activities is required for dendritic plasticity and synaptogenesis in the supraoptic nucleus.
Topics: Animals; Arginine Vasopressin; Calcium; Dendrites; Excitatory Amino Acid Antagonists; Fluorescent Dyes; Hormone Antagonists; In Vitro Techniques; Indoles; Microinjections; Morpholines; N-Methylaspartate; Neuronal Plasticity; Neurons; Oxytocin; Presynaptic Terminals; Pyrrolidines; Rats; Receptors, N-Methyl-D-Aspartate; Spiro Compounds; Supraoptic Nucleus; Synapses; Synaptic Transmission | 2002 |
Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist
Topics: Adrenocorticotropic Hormone; Animals; Anti-Anxiety Agents; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Cattle; Cell Membrane; Cells, Cultured; CHO Cells; Cricetinae; Dehydration; Humans; Hypothalamus; In Vitro Techniques; Kinetics; Male; Morpholines; Rats; Rats, Sprague-Dawley; Spiro Compounds; Stress, Psychological | 2002 |
Vasopressin increases type IV collagen production through the induction of transforming growth factor-beta secretion in rat mesangial cells.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Cells, Cultured; Collagen Type IV; Dose-Response Relationship, Drug; Male; Mesangial Cells; Morpholines; Piperidines; Rats; Rats, Wistar; Spiro Compounds; Transforming Growth Factor beta | 2008 |
Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Deamino Arginine Vasopressin; Diuretics; Dose-Response Relationship, Drug; Furosemide; Male; Morpholines; Rats; Rats, Wistar; Receptors, Vasopressin; Sodium; Spiro Compounds; Urine | 2008 |
Modulation of aquaporin-2/vasopressin2 receptor kidney expression and tubular injury after endotoxin (lipopolysaccharide) challenge.
Topics: Acute Kidney Injury; Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Arginine Vasopressin; Creatinine; Endotoxins; Epinephrine; Glomerular Filtration Rate; Injections, Intraperitoneal; Kidney; Lipopolysaccharides; Male; Morpholines; Proteinuria; Random Allocation; Rats; Rats, Wistar; Receptors, Vasopressin; Renal Circulation; RNA, Messenger; Sepsis; Spiro Compounds; Uteroglobin; Vasoconstrictor Agents | 2008 |
Effect of the cGMP pathway on AQP2 expression and translocation: potential implications for nephrogenic diabetes insipidus.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Arginine; Arginine Vasopressin; Atrial Natriuretic Factor; Cell Line; Cells, Cultured; Cyclic GMP; Diabetes Insipidus, Nephrogenic; Humans; Kidney Tubules, Collecting; Male; Models, Animal; Morpholines; Protein Biosynthesis; Receptors, Vasopressin; Signal Transduction; Spiro Compounds | 2010 |